Ligand Pharmaceuticals Reports 123% Revenue Growth and $117.3 Million Net Income in Q3 2025

Ligand Pharmaceuticals Incorporated reported significant financial growth in its third quarter of 2025, with total revenues and other income reaching $115.5 million, a 123% increase from $51.8 million in the same period last year. This surge was primarily driven by a substantial rise in royalties, which increased by 47% to $46.6 million, largely due to higher sales of products such as Filspari and Ohtuvayre. Additionally, contract revenue and other income saw a remarkable increase of 320%, totaling $58.2 million, bolstered by a $53.1 million gain from the Pelthos Transaction, which involved the divestiture of Ligand's subsidiary, LNHC, Inc.

In terms of profitability, Ligand reported a net income of $117.3 million for Q3 2025, compared to a net loss of $7.2 million in Q3 2024. This turnaround was attributed to the aforementioned revenue growth and a decrease in operating costs as a percentage of revenue, which fell to 52% from 94% year-over-year. The company’s operating income for the quarter was $54.9 million, a significant increase from $3.1 million in the prior year. For the nine months ending September 30, 2025, net income was $79.7 million, compared to $27.1 million in the same period of 2024.

Ligand's strategic developments included the completion of the Pelthos Transaction, which not only provided immediate financial benefits but also positioned the company to earn royalties on the newly launched Zelsuvmi, a treatment for molluscum contagiosum. The company also made notable investments in Arecor and Orchestra BioMed, acquiring economic rights to their partnered programs, which are expected to generate future revenue streams. Furthermore, Ligand issued $460 million in convertible senior notes due 2030, enhancing its liquidity and financial flexibility.

Operationally, Ligand's cash and cash equivalents increased to $139.4 million as of September 30, 2025, up from $72.3 million at the end of 2024. The company also reported a significant rise in short-term investments, which totaled $525.1 million, compared to $183.9 million at the end of the previous fiscal year. Ligand's employee headcount remained stable, with no significant changes reported in staffing levels.

Looking ahead, Ligand anticipates continued growth driven by its diverse portfolio of biopharmaceutical products and strategic partnerships. The company expects to benefit from the ongoing commercialization of Zelsuvmi and other partnered products, alongside its investments in innovative therapies. However, management cautioned that future results may be influenced by market conditions, regulatory approvals, and the performance of its partner programs.